Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Index benchmarks provide a transparent yardstick for performance, helping investors gauge risk-adjusted returns and make informed choices.
27,627 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
FuelCell Energy slumped 22% on Monday as investors rebalanced the AI-powered hydrogen rally, with Plug Power down 12%...
ServiceNow climbs as investors chase AI-driven growth in enterprise software, with Dell's recent results helping lift...
Citi warns that the stock market frothiest since the global financial crisis has created vulnerabilities, but says pa...
In a landmark move, australia’s richest person just disclosed a stake worth more than $1 billion in SpaceX as the pri...
A top chip maker delivered a surprising quarterly beat, reviving investor appetite and igniting a debate over AI memo...
Energy markets pivot as renewables rise and fossil fuels adapt; several penny stocks are drawing attention for their ...
A December 2025 Florida Tax Watch study identifies the ten Florida counties with the lowest property taxes, led by Un...
Costco has delivered outsized gains over the past decade, while Walmart has paced a modern omnichannel comeback. The ...
Microsoft kicks off 2026 with a rough start as earnings beat clashes with a surge in capital expenditures. Traders de...
JPMorgan downgraded Wix.com to Underweight and cut its price target to $91, citing slower core growth and volatile ma...
Investors are moving cash into ultra-short and short-term bond funds as yields edge above savings rates. A market hos...